

# MAHARASHTRA POLLUTION CONTROL BOARD



Minutes of 6<sup>th</sup> meeting of Technical Committee (2018-19) for assessment of application of under change in product-mix held on 27/3/2019 at 03.30 pm at Kalpataru Point, 3<sup>rd</sup> Floor, Sion.

The Technical Committee meeting for assessment of application of under change in product-mix of the Board was held on 27/3/2018. The following members of the Technical Committee were present for the meeting:

1. Shri P.K.Mirashke, Assistant Secretary (Tech), MPCB  
Chairman
2. Dr B.R.Naidu, Zonal Officer, CPCB, Vadodara  
Member
3. Shri A. M. Pimpalkar, Scientist -1, Environment Dept, GoM  
Member
4. Shri N.N.Gurav, Regional Officer, HQ, MPCB  
Member convener

Shri Anurag Garg, Associate Prof. IIT, Mumbai, Dr. Tuhin Banerjee, Scientist Fellow, NEERI, Mumbai and Dr. Prakash P. Wadgaonkar, Chief Scientist, NCL, Pune could not attend the meeting. Leave of absence was granted to them.

The Chairman of the Committee welcomed the Committee members and the minutes of the 4<sup>th</sup> meeting of the Technical Committee (2018-19) were confirmed. Two agenda items were placed before the meeting. Committee deliberated on the agenda items and following decisions were taken.

Sr. No.	Name of Industry	Recommendations
1	BALAJI AMINES LTD Gut.No.197, Tamalwadi. MPCB-CONSENT- 0000059624	Industry representative were not present, hence case was deferred by the committee for the next meeting.
2	Rashtriya Chemicals & Fertilizers Ltd. RCF LTD, THAL, TALUKA -ALIBAG, RAIGAD, MAHARASHTRA	PP gave presentation on amendment in existing consent under change in product-mix for installation of one Process Air compressor and additional heat recovery steam generator by replacing existing two Process Air compressors. After interaction with the PP, it was noted that,  1. Environmental Clearance was granted to the unit by MOEFCC ( F.No. J-11011/862/2008-IA-II(I)) dated 10-June 2009 for expansion by De- bottlenecking of Thal Ammonia plant to 2 x 1750 TPD and to Urea plant to 3x 2040 MTPD.

Sr. No.	Name of Industry	Recommendations
MPCB-CONSENT-0000059883		<p>2. Environmental Clearance was further granted to the unit by MOEFCC (F.No. J-11011392/2014-IA-II (I)) dated 10-Feb-2016 for installation of gas turbine generator and heat recovery steam Generator under energy reduction scheme for Urea unit operation.</p> <p>3. PP has valid consent to operate from the Board dated 29.11.2018 valid till 31.12.2022.</p> <p>4. PP reported that, they approached product mix committee as per EDS of MoEF &amp; CC.</p> <p>5. <b>PP submitted proposal for:</b></p> <p><b>Installation of utility systems as given:</b></p> <p>a. One No. New Gas Turbine Driven Process Air compressor (PAC-IV) of 120,000 NMM3/hr capacity</p> <p>b. Additional Heat Recovery System Generator (HRSG) of capacity 100 MT/hr</p> <p><b>Following existing utility systems will be stopped after the proposed installations:</b></p> <p>a. Two No. Process Air compressor (Out of 03 No. existing).</p> <p>b. Existing Boiler of total capacity 275 TPH.</p> <p>The overall production quantity after the proposed utility systems installation will remain unchanged.</p> <p>6. PP has submitted below reduction in various utilities after the proposed installations.</p> <p>a. Make up Raw water consumption will get reduced from existing 45357 m3/day to 41873 m3 /day (Net reduction of 3484 m3 /day)</p> <p>b. Fuel gas (Natural gas ) consumption will get reduced from existing 35843 Sm3/hr to 28931Sm3 /hr (Net Reduction by 6912 Sm3 /hr)</p> <p>c. Power requirement will get reduced from 46 MW to 44.2 MW ( Net reduction of 1.8 MW)</p> <p>d. HP Steam requirement will get reduced from existing 349 MTPH to 227 MTPH ( Net reduction by 122 MTPH)</p> <p>PP has received NIPPL certificate from MITCON Consultancy and Engineering Services Ltd.</p> <p>7. NIPPL certificate submitted does not shows any quantitative pollution load reduction. PP has been asked to submit the quantified pollution load before and after installation of proposed utility systems.</p>




Sr. No.	Name of Industry	Recommendations																																																																																										
2	M/S Lupin Limited T-142, MIDC Tarapur  MPCB-CONSENT-0000049334	<p>Finally, after due deliberations, as there is no change in product type or quantities, Committee recommended the case for the proposed utility systems installations and case may be forwarded to CAC for further process with a condition to submit the revised NPL certificate showing quantified pollution load. PP gave presentation on renewal of Existing Consent to Operate along with change in product-mix. After interaction with the PP, it was noted that,</p> <p>a. Environmental Clearance granted to the unit by SEAC (Lupin)-2009/153/CR.167/TC-1} on 16<sup>th</sup> November, 2010 for the expansion with total production capacity of various Active Pharmaceutical ingredient (API) products 1449.75 MTPA.</p> <p>b. PP had a consent to operate from the Board dated 04.03.2017 which was valid till 30.04.2018 for production of 1449.41 MTPA of various Active Pharmaceutical ingredient (API) products.</p> <p>c. PP submitted proposal for:</p>																																																																																										
	<table border="1"> <thead> <tr> <th data-bbox="820 674 906 1185">Sr. No</th> <th data-bbox="820 1185 906 1803">Name of Product</th> <th data-bbox="820 1803 906 1991">Existing, Consented (TPA)</th> <th data-bbox="820 1991 906 2179">Proposed Addition (+)/Deletion (-) (TPA)</th> <th data-bbox="820 2179 906 2558">Total (TPA)</th> </tr> </thead> <tbody> <tr><td>1.</td><td>Rifa S,Rifa O &amp; Rifampicin</td><td>360</td><td>(+) 5</td><td>365</td></tr> <tr><td>2.</td><td>Rifaximin</td><td>50</td><td>(-) 5</td><td>45</td></tr> <tr><td>3.</td><td>Lovastatin</td><td>9.89</td><td>(+) 6.11</td><td>16</td></tr> <tr><td>4.</td><td>Simvastatin</td><td>60.5</td><td>(-) 20.5</td><td>40</td></tr> <tr><td>5.</td><td>Sertraline</td><td>56</td><td>(+) 13.5</td><td>69.5</td></tr> <tr><td>6.</td><td>Losartan potassium</td><td>62.4</td><td>(-) 12.4</td><td>50</td></tr> <tr><td>7.</td><td>Valsartan</td><td>46.22</td><td>(-) 26.22</td><td>20</td></tr> <tr><td>8.</td><td>Duloxetine</td><td>10</td><td>(+) 8</td><td>18</td></tr> <tr><td>9.</td><td>Irbesartan</td><td>18.47</td><td>(-)3.47</td><td>15</td></tr> <tr><td>10.</td><td>Quetiapine Fumerate</td><td>36.35</td><td>(+) 23.65</td><td>60</td></tr> <tr><td>11.</td><td>Pyrazinamide</td><td>270.74</td><td>(-) 99.22</td><td>166.52</td></tr> <tr><td>12.</td><td>Levetiracetam</td><td>350</td><td>(+) 58</td><td>408</td></tr> <tr><td>13.</td><td>Lamivudine</td><td>1.36</td><td>(-) 1.36</td><td>0</td></tr> <tr><td>14.</td><td>Colesevalam</td><td>21.6</td><td>(-) 21.5</td><td>0.1</td></tr> <tr><td>15.</td><td>Abacavir (Hydrochloride/Sulphate)</td><td>1.28</td><td>(+) 14.72</td><td>16</td></tr> <tr><td>16.</td><td>Amlodipine Besilate</td><td>11.38</td><td>(+) 9.62</td><td>21</td></tr> <tr><td>17.</td><td>Escitalopram Oxalate</td><td>4.72</td><td>(-) 1.72</td><td>3</td></tr> </tbody> </table>	Sr. No	Name of Product	Existing, Consented (TPA)	Proposed Addition (+)/Deletion (-) (TPA)	Total (TPA)	1.	Rifa S,Rifa O & Rifampicin	360	(+) 5	365	2.	Rifaximin	50	(-) 5	45	3.	Lovastatin	9.89	(+) 6.11	16	4.	Simvastatin	60.5	(-) 20.5	40	5.	Sertraline	56	(+) 13.5	69.5	6.	Losartan potassium	62.4	(-) 12.4	50	7.	Valsartan	46.22	(-) 26.22	20	8.	Duloxetine	10	(+) 8	18	9.	Irbesartan	18.47	(-)3.47	15	10.	Quetiapine Fumerate	36.35	(+) 23.65	60	11.	Pyrazinamide	270.74	(-) 99.22	166.52	12.	Levetiracetam	350	(+) 58	408	13.	Lamivudine	1.36	(-) 1.36	0	14.	Colesevalam	21.6	(-) 21.5	0.1	15.	Abacavir (Hydrochloride/Sulphate)	1.28	(+) 14.72	16	16.	Amlodipine Besilate	11.38	(+) 9.62	21	17.	Escitalopram Oxalate	4.72	(-) 1.72	3	
Sr. No	Name of Product	Existing, Consented (TPA)	Proposed Addition (+)/Deletion (-) (TPA)	Total (TPA)																																																																																								
1.	Rifa S,Rifa O & Rifampicin	360	(+) 5	365																																																																																								
2.	Rifaximin	50	(-) 5	45																																																																																								
3.	Lovastatin	9.89	(+) 6.11	16																																																																																								
4.	Simvastatin	60.5	(-) 20.5	40																																																																																								
5.	Sertraline	56	(+) 13.5	69.5																																																																																								
6.	Losartan potassium	62.4	(-) 12.4	50																																																																																								
7.	Valsartan	46.22	(-) 26.22	20																																																																																								
8.	Duloxetine	10	(+) 8	18																																																																																								
9.	Irbesartan	18.47	(-)3.47	15																																																																																								
10.	Quetiapine Fumerate	36.35	(+) 23.65	60																																																																																								
11.	Pyrazinamide	270.74	(-) 99.22	166.52																																																																																								
12.	Levetiracetam	350	(+) 58	408																																																																																								
13.	Lamivudine	1.36	(-) 1.36	0																																																																																								
14.	Colesevalam	21.6	(-) 21.5	0.1																																																																																								
15.	Abacavir (Hydrochloride/Sulphate)	1.28	(+) 14.72	16																																																																																								
16.	Amlodipine Besilate	11.38	(+) 9.62	21																																																																																								
17.	Escitalopram Oxalate	4.72	(-) 1.72	3																																																																																								

Sr. No.	Name of Industry	Recommendations			
18	Sumatriptan Succinate	0.05	(-) 0.05	0	
19	Tolterodine Tartarate	0.07	(-) 0.07	0	
20	Celecoxib	21.8	(-) 3.8	18	
21	Ethambutol	4.02	(+) 8.98	13	
22	Fenofibrate/Choline Fenofibrate	28.81	(+) 8.71	37.52	
23	Rifabutin	0.35	(+) 0.65	1	
24	zolpidem tartarate	0.25	(+) 0.55	0.8	
25	Imipramine pamoate/ Imipramine Hcl	1.69	(-) 1.19	0.5	
26	Lansoprazole	2	(-) 1.0	1	
27	Rabeprazole	0.55	(+) 0.25	0.8	
28	Carvedilol /Carvedilol Phosphate	0.63	(-) 0.63	0	
29	Telmisartan	1.07	(-) 1.07	0	
30	Risperidone	0.33	(-) 0.18	0.15	
31	Azythromycin	2.05	(-) 0.05	2	
32	Gatifloxacin	0.01	(+) 0.01	0.02	
33	Ziprasidone	2.81	(-) 0.81	2	
34	Desloratadine	0.71	(-) 0.21	0.5	
35	Memantine	0.33	(+) 1.17	1.5	
36	Eszopiclone	0.05	(+) 0.05	0.1	
37	Feno SLS /Ethanamide	0.4	(-) 0.2	0.2	
38	Tenofovir	0.5	(+) 5.0	5.5	
39	Emitricitabine	0.01	(+) 3.99	4	
40	Ezetimibe	0.01	(+) 1.99	2	
41	R& D batches	10	(+) 10	20	
42	Ranolazine	0	(+) 25.00	25	
43	Armodafinil	0	(+) 0.5	0.5	
44	Capreomycin Sulphate	0	(+) 0.1	0.1	
45	Calcium – L-5- Methyl TetraHydrofolate	0	(+) 0.1	0.1	
<b>TOTAL</b>		<b>1449.41</b>	<b>0</b>	<b>1449.41</b>	

Sr. No.

Name of Industry

Recommendations

## List of By-products:-

Sr. No	Name of Product	Existing, Consented (TPA)	Proposed Addition (+)/ Deletion (-) (TPA)	Total (TPA)
1.	Trans sentaline	182.5	(+)40.46	222.96
2.	Piperazine di acetate	91.25	(-) 18.79	72.46
3.	2 Amino 4 methyl Pyridine	12.62	(-) 3.75	8.87
4.	Tributyl tin Chloride	63.5	(-) 36.72	26.78
5.	Hydroxy Ethoxy Ethyl Piperazine	7.37	(-) 7.37	0
6.	Di Methyl Butanoic acid	57.97	(-) 20.73	37.24
7.	R-R mandelate salt	99.97	(-) 11.48	88.49
8.	Sodium Sulphate	142.5	(-) 142.5	0
9.	Immidazole Hydrochloride	0	(+) 29.68	29.68
10.	Tri Ethyl Amine	0	(+)77.34	77.34
11.	Mandelic acid	0	(+)36.69	36.69
12.	Di iso propyl ethyl amine	0	(+)33.58	33.58
	<b>TOTAL</b>	<b>657.68</b>	<b>(-) 23.59</b>	<b>634.09</b>

The overall production quantity after product mix will be 1449.41 MTA as per existing consent to operate. The overall By product quantity will reduce from 657.68 TPA to 634.09 TPA.

d. PP has submitted pollution load details as below.

- > Water requirement reduced from 2269.18 CMD to 2263.5 CMD after proposed product mix.
- > Effluent hydraulic load reduced from 1134.5 CMD to 1127.1 CMD after proposed product mix.
- > Organic load reduced from 13001.58 kg/ day to 12794.99 kg/ day. TDS load reduced from 6533.11 kg/ day to 5509.54 kg/ day.
- > Existing Boilers (6 nos), Process Stacks (27 nos), Power Generator sets (2 nos) and DG sets (9nos) will be utilized after product mix. However, there will not be additional fuel required. Existing Fuel requirement will remain same. Air emissions quantity will reduce from 1625 kg/ day to 1599 kg/ day.
- > There will be no increase in Hazardous waste quantity after product mix.





Sr. No.	Name of Industry	Recommendations
3	<p>Indo Amines Limited (Formerly known as Classic Oil Limited.) W-44, Dombivli MIDC Phase-II, Manpada Road, Dombivli</p> <p>MPCB-CONSENT-0000001099</p>	<p>e. PP has received NIPPL certificate from Goldfin Engineering Systems Pvt Ltd. dated 20<sup>th</sup> February 2019.</p> <p>f. PP has indicated that their by-products are sent to the third parties for recovery / processing and are taken back in the process in PP's manufacturing facility. Committee has suggested following points for such by-products:</p> <ul style="list-style-type: none"> <li>● All by-products which are sent outside the PP's premises for recovery/processing, shall be included as Hazardous waste with mode of disposal as <b>"Recycle through authorized recycler and captive consumption only"</b>. All such recyclers should apply to MPCB for authorization under Rule-9 and PP shall make an MOU with recyclers &amp; submit to Board office.</li> <li>h. By-products (HW) sent to recyclers by following manifest system.</li> </ul> <p>Finally, after due deliberations, it was decided to recommend the case for change in product under product mix with a condition to dispose the by-product as Hazardous Waste and shall comply the provision of HW Rules for sale/disposal of by-products.</p> <p>Industry representative were not present, hence case was deferred by the committee for the next meeting.</p>
	<p>Deepak Nitrite Limited Plot Nos - 1-7,26-31,MIDC,Dhatav,Roha-402116</p> <p>MPCB-CONSENT-0000001099</p>	<p>PP gave presentation on amendment in existing consent for change in product-mix. After interaction with the PP, it was noted that,</p> <ol style="list-style-type: none"> <li>1. Environmental Clearance granted to the unit vide No. J-11011/363/2016/IA II (I) dated 12/04/2018</li> <li>2. Consent to Operate granted by Board vide No. Format 1.0/AST/UAN No. 0000031393/O/CC-1803000099, dated 01/3/2018 which is valid upto 30/6/2019</li> <li>3. Total production capacity mentioned in EC is 740 MT/M, whereas PP submitted proposed product capacity of 790 MT/M under product mix application.</li> </ol>




Sr. No.	Name of Industry	Recommendations
		<p>4. PP has not given break up of products &amp; only mentioned as "Pilot plant products (Synthetic organic chemicals). Considering the above, it was noted that, there will be increase in total production capacity. PP during presentation informed, they will resubmit the proposal under product mix. Finally, after due deliberations, it was decided to defer the case and place before committee after revised proposal.</p>

The meeting ended with vote of thanks to Chair.

  
 (N.K. Gurav)  
 Regional Officer (HQ)  
 Member convener

  
 (P.K. Mirashe)  
 Asst. Secretary (Tech)  
 Chairman of Product Mix Committee